MSH6 and colorectal carcinoma: These findings suggest that, given the substantially lower lifetime risk of developing CRC and considering the negative impact of biennial surveillance on quality of life, surveillance intervals for individuals with MSH6 and PMS2 gPVs could potentially be safely extended.